AURA
Aura Biosciences, Inc.·Healthcare
7.66
0.657%(+0.05)
Close PriceLast Updated: — ET
52W L: $4.7352W H: $9.54
AURA NEWS
marketbeat.com
9h ago
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Aura Biosciences NASDAQ: AURA is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal melanoma nears completion, newly appointed CEO Natalie Holles said during a fireside chat at TD Cowen's seventh annual Oncology Innovation Summit.
marketbeat.com
May 19
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences NASDAQ: AURA executives outlined the company's strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company's initial development focus while also discussing ongoing work in non-muscle invasive bladder cancer.
globenewswire.com
May 19
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura's new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles' offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
globenewswire.com
May 12
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on Tuesday, May 19, 2026.
globenewswire.com
May 11
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance sheet with oversubscribed $299 million equity financing; cash position expected to fund operations into 2H 2028 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights. “We are entering a pivotal period for Aura as we advance our Phase 3 CoMpass trial toward enrollment completion and potential registration,” said Natalie Holles, Chief Executive Officer of Aura Biosciences.
globenewswire.com
May 6
AMG Reports Better than Expected First Quarter 2026 Results
Amsterdam, 6 May 2026 (Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) reports first quarter 2026 adjusted EBITDA of $44 million. This was a 2% improvement compared to the $43 million in the fourth quarter of 2025 and exceeded our guidance that the first quarter 2026 would be down sequentially. This better-than-expected performance in the current quarter was mainly driven by AMG Vanadium which included the consolidation of AURA beginning January 1, 2026. Beyond circular molybdenum, AURA brought recycled tungsten into our critical materials portfolio, and the tungsten price performance helped their results. Despite anticipated lower cash generation at the beginning of the year, AMG ended the quarter with a strong balance sheet highlighted by our $403 million of total liquidity as of March 31, 2026. This figure does not include the $127 million of proceeds from the capital increase.
